Kyverna Therapeutics, Inc. KYTX Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s short- and long-term operating lease liabilities?
- Kyverna Therapeutics, Inc. (KYTX) reported short- and long-term operating lease liabilities of -$503K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s short- and long-term operating lease liabilities changed year-over-year?
- Kyverna Therapeutics, Inc.'s short- and long-term operating lease liabilities increased by 47.8% year-over-year, from -$963K to -$503K.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s short- and long-term operating lease liabilities?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s short- and long-term operating lease liabilities has grown at a 41.0% compound annual growth rate (CAGR), from -$1.68M to -$3.34M.